相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma
Dongjiang Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications
Narasimha Kumar Karanam et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2021)
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
J. Bryan Iorgulescu et al.
CLINICAL CANCER RESEARCH (2021)
Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression
Chirag B. Patel et al.
NEOPLASIA (2021)
Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models
Helena Mumblat et al.
LUNG CANCER (2021)
Permeabilizing Cell Membranes with Electric Fields
Alondra A. Aguilar et al.
CANCERS (2021)
Senescence and associated blood-brain barrier alterations in vitro
Ellaine Salvador et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2021)
T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields
Gil Diamant et al.
JOURNAL OF IMMUNOLOGY (2021)
In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso
Roni Blatt et al.
FRONTIERS IN ONCOLOGY (2021)
Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy
Narasimha Kumar Karanam et al.
TRANSLATIONAL RESEARCH (2020)
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
Tali Voloshin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Tumor treating fields effects on the blood-brain barrier in vitro and in vivo.
Ellaine Salvador et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A Theoretical Study on the Biophysical Mechanisms by Which Tumor Treating Fields Affect Tumor Cells During Mitosis
Xing Li et al.
IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING (2020)
Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Actin Dynamics
Tali Voloshin et al.
CANCERS (2020)
Kidney Ischemia/Reperfusion Injury Induces Changes in the Drug Transporter Expression at the Blood-Brain Barrier in vivo and in vitro
Malgorzata Burek et al.
FRONTIERS IN PHYSIOLOGY (2020)
Neuroprotective Effects of Isosteviol Sodium in Murine Brain Capillary Cerebellar Endothelial Cells (cerebEND) After Hypoxia
Nils Roesing et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2020)
Membrane Electroporation and Electropermeabilization: Mechanisms and Models
Tadej Kotnik et al.
ANNUAL REVIEW OF BIOPHYSICS, VOL 48 (2019)
Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis
Lukas Berkelmann et al.
SCIENTIFIC REPORTS (2019)
Efficacy and Thermal Safety of Tumor Treating Fields Delivered to the Thorax: A Simulation-Based Study
Z. Bomzon et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells
Eun Ho Kim et al.
ONCOGENE (2019)
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
Karen G. de la Cruz-Lopez et al.
FRONTIERS IN ONCOLOGY (2019)
Mitotic slippage: an old tale with a new twist
Debottam Sinha et al.
CELL CYCLE (2019)
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial
S. A. Toms et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study
Fernando Rivera et al.
PANCREATOLOGY (2019)
BLOOD-BRAIN BARRIER: FROM PHYSIOLOGY TO DISEASE AND BACK
Melanie D. Sweeney et al.
PHYSIOLOGICAL REVIEWS (2019)
Final results of Phase II STELLAR trial: TTFields with chemotherapy in unresectable malignant pleural mesothelioma
Giovanni Luca Ceresoli et al.
CANCER RESEARCH (2019)
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
Amber J. Giles et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Transducer array configuration optimization for treatment of pancreatic cancer using Tumor Treating Fields (TTFields)
Ariel Naveh et al.
CANCER RESEARCH (2018)
Tumor treating fields exert cellular and immunologic effects
Eric T. Wong et al.
CANCER RESEARCH (2018)
Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study
Ignace Vergote et al.
GYNECOLOGIC ONCOLOGY (2018)
Tubulin's response to external electric fields by molecular dynamics simulations
Joshua J. Timmons et al.
PLOS ONE (2018)
Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy
Yunhui Jo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
A Review on Electroporation-Based Intracellular Delivery
Junfeng Shi et al.
MOLECULES (2018)
AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields)
Anna Shteingauz et al.
CELL DEATH & DISEASE (2018)
Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide
H. Ian Robins et al.
FRONTIERS IN ONCOLOGY (2018)
Tumor treating fields increases membrane permeability in glioblastoma cells
Edwin Chang et al.
CELL DEATH DISCOVERY (2018)
Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition
Almuth F. Kessler et al.
CELL DEATH DISCOVERY (2018)
Microtubule destabilising agents: far more than just antimitotic anticancer drugs
Darcy Bates et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Larissa Siqueira Penna et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells
Moshe Giladi et al.
RADIATION ONCOLOGY (2017)
Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines
Narasimha Kumar Karanam et al.
CELL DEATH & DISEASE (2017)
Biological activity of tumor-treating fields in preclinical glioma models
Manuela Silginer et al.
CELL DEATH & DISEASE (2017)
Migrating into the Tumor: a Roadmap for T Cells
Lieke L. van der Woude et al.
TRENDS IN CANCER (2017)
Corticosteroids compromise survival in glioblastoma
Kenneth L. Pitter et al.
BRAIN (2016)
Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
Tali Voloshin et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation
Eun Ho Kim et al.
ONCOTARGET (2016)
Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis
Eun Ho Kim et al.
ONCOTARGET (2016)
An Overview of Sub-Cellular Mechanisms Involved in the Action of TTFields
Jack A. Tuszynski et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2016)
Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma (vol 113, pg 232, 2015)
E. T. Wong et al.
BRITISH JOURNAL OF CANCER (2015)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit
Nidhi Gera et al.
PLOS ONE (2015)
Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells
Moshe Giladi et al.
SCIENTIFIC REPORTS (2015)
Predicting the electric field distribution in the brain for the treatment of glioblastoma
Pedro C. Miranda et al.
PHYSICS IN MEDICINE AND BIOLOGY (2014)
Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields
Moshe Giladi et al.
PANCREATOLOGY (2014)
Alternating Electric Fields (Tumor-Treating Fields Therapy) Can Improve Chemotherapy Treatment Efficacy in Non-Small Cell Lung Cancer Both In Vitro and In Vivo
Moshe Giladi et al.
SEMINARS IN ONCOLOGY (2014)
The pivotal role of astrocytes in an in vitro stroke model of the blood-brain barrier
Winfried Neuhaus et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2014)
Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma
Eric T. Wong et al.
CANCER MEDICINE (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs
Bakhos A. Tannous et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer
Miklos Pless et al.
LUNG CANCER (2013)
A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2
Katharina Schlacher et al.
CANCER CELL (2012)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp et al.
EUROPEAN JOURNAL OF CANCER (2012)
Addition of NMDA-receptor antagonist MK801 during oxygen/glucose deprivation moderately attenuates the upregulation of glucose uptake after subsequent reoxygenation in brain endothelial cells
Winfried Neuhaus et al.
NEUROSCIENCE LETTERS (2012)
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Laura Senovilla et al.
SCIENCE (2012)
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Weibo Luo et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Analysis of protein dynamics at active, stalled, and collapsed replication forks
Bianca M. Sirbu et al.
GENES & DEVELOPMENT (2011)
Spindle Poisons and Cell Fate: A Tale of Two Pathways
Daniel R. Matson et al.
MOLECULAR INTERVENTIONS (2011)
Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs
Eilon D. Kirson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Heather R. Christofk et al.
NATURE (2008)
A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors
Marc Salzberg et al.
ONKOLOGIE (2008)
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Eilon D. Kirson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The spindle-assembly checkpoint in space and time
Andrea Musacchio et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Differential susceptibility of cerebral and cerebellar murine brain microvascular endothelial cells to loss of barrier properties in response to inflammatory stimuli
Christine Silwedel et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
A mitotic septin scaffold required for mammalian chromosome congression and segregation
ET Spiliotis et al.
SCIENCE (2005)
Disruption of cancer cell replication by alternating electric fields
ED Kirson et al.
CANCER RESEARCH (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The spindle checkpoint: Structural insights into dynamic signalling
A Musacchio et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
分享论文
